【レポートの概要（一部）】
1. Report Overview
1.1 Top Stem Cell Technology Companies: Overview
1.2 Global Stem Cell Technology Market Segmentation
1.3 Why You Should Read This Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
1.11 Glossary
2. The Global Stem Cell Technology and Applications Market 2015-2025
2.1 The Stem Cell Technologies and Applications Market in 2014
2.2 Non-therapeutic Applications Constitutes the Largest Segment in 2014, Oncology the Largest Therapeutic Area
2.3 Global Stem Cell Technology and Applications Market: Regional Breakdown, 2014
2.4 Global Stem Cell Technology and Applications Market Forecast 2015-2025
2.5 Fast Growth Owing to Therapeutic Potential, Drug Screening and Emerging Markets
2.6 Global Stem Cell Technology and Applications Market Forecast by Therapeutic Segment 2015-2025
2.7 Therapeutic Applications to Overtake Non-Therapeutic Applications in 2020
2.8 How Will Market Shares for the Different Segments Within the Stem Cells Market Change from 2014-2025?
2.9 Drivers and Restraints for the Stem Cell Technology and Applications Market, 2015-2025
3. Leading US Stem Cell Technology Companies
3.1 Regulation, Patentability and ‘Homologous Use’ in the US
3.1.1 Embryonic Stem Cell Research Remains Controversial in the US
3.2 Osiris Therapeutics
3.2.1 Developed and then Sold the Rights to Osteocel and Prochymal
3.2.2 Grafix Reports Impressive Clinical Trial Results, Now Available in More Sizes
3.2.2.1 Is Grafix Really a ‘Stem Cell Product’?
3.2.3 OvationOS: Stem Cell Product for Regeneration of Bone Tissue
3.2.4 Cartiform – Launched to Address a Potential $500m Market
3.2.4.1 Partnership with Arthrex for the Commercialisation and Development of Cartiform
3.2.5 Osiris Therapeutics Stem Cell Revenue Forecast 2014-2025
3.2.6 Osiris Therapeutics: Optimistic Outlook for that Leading Stem Cell Company
3.3 NeoStem: Generating Revenue through Services whilst Developing Stem Cell Therapies
3.3.1 Growth Through Acquisitions – Including PCT, Amorcyte, Athelos and California Stem Cell Inc.
3.3.2 NBS10 – Lead Candidate in NeoStem’s Ischaemic Repair Programme
3.3.2.1 NBS10 Shows Positive Initial Results From 2014 Phase II Clinical Trial
3.3.3 VSEL Technology: Potential to Treat Ocular Diseases and Chronic Wounds?
3.3.4 NeoStem Revenues 2011-2014
3.3.5 NeoStem Outlook in Summary: NBS10 Could Cater to 160,000 Patients a Year
3.4 Orthofix – Two Orthobiologic Products Already on the Market
3.4.1 Trinity Evolution and Trinity Elite – Over 90,000 Procedures to Date
3.4.1.1 Trinity Elite and Trinity Evolution: Revenue Forecast 2014-2025
3.4.2 Orthofix Outlook in Summary: High Revenues from Trinity Products but Will Have to Demonstrate Efficacy
3.5 NuVasive: Owns the Leading Stem Cell Orthobiologic
3.5.1 Osteocel to Osteocel Plus: Changes and Challenges
3.5.1.1 Osteocel Plus: The Leading Stem Cell Orthobiologic
3.5.1.2 Osteocel Plus: Is it Better than Autograft?
3.5.1.3 Osteocel Plus: Revenue Forecast 2015-2025
3.5.2 NuVasive Outlook in Summary: Osteocel Plus Revenues Will Continue to Grow, Although will Face Increased Competition in Coming Years
3.6 AlloSource: Non-Profit which Markets AlloStem and Processes Osteocel for NuVasive
3.6.1 AlloStem: Stem Cell Bone Growth Substitute
3.7 RTI Surgical: Company adds to their Orthobiologic Portfolio with Map3
3.7.1 Map3: RTI Surgical is Competing with Established Players like NuVasive and Orthofix
3.8 Vericel Corporation (Formerly Aastrom Biosciences)
3.8.1 Ixmyelocel-T
3.8.2 Vericel Focusing on Dilated Cardiomyopathy (DCM) and Away From CLI
3.8.3 Ixmyelocel-T: Orphan Drug Designation and Undergoing Phase 2b Trial for DCM and Phase 1/2 for Craniofacial Reconstruction
3.8.4 Vericel Corporation Revenues 2011-2013
3.8.5 Vericel Corporation: Outlook in Summary
3.9 Bioheart
3.9.1 MyoCell: Autologous ‘Muscle Stem Cell’ Therapy
3.9.1.1 MyoCell: Undergoing Phase 2/3 (‘MARVEL’) Trial
3.9.1.2 MyoCell: MIRROR Phase 3 Trial Progress
3.9.2 MyoCell SDF-1: Improved Version of MyoCell
3.9.2.1 MyoCell SDF-1 Phase 1 Trial (REGEN) Trial
3.9.3 Adipocell for CLI in Phase 1/2, and Being Investigated for RI and Degenerative Disc Disease
3.9.3.1 Adipocell: Also Being Investigated for DDD, COPD and Dry Macular Degeneration
3.9.4 Bioheart Revenues 2010-2013
3.9.5 Bioheart: Outlook in Summary
3.10 Neuralstem
3.10.1 NSI-566 Completes Phase 2 for ALS, Long-Term Follow-Up Data is Promising
3.10.2 NSI-566 for Chronic Spinal Cord Injury: Phase 1, expected to Begin Phase 1/2 for Acute Spinal Cord Injury Q1 2015
3.10.3 NSI-566 for Ischaemic Stroke: Phase 1/2 Trials Underway in China
3.10.4 Neuralstem: Preclinical Investigation for 11 Other Indications
3.10.5 Neuralstem Revenues 2010-2013
3.10.6 Neuralstem Outlook in Summary: Aiming to Treat a Wide Range of Conditions – Potential Revenues are Huge
3.11 Ocata Therapeutics (Formerly Advanced Cell Technology)
3.11.1 Broad Intellectual Property Portfolio and Recent Funding from Lincoln Park Capital
3.11.2 MA09-hRPE in Two Phase 1/2 Trials for Stargardt’s Macular Degeneration
3.11.2.1 Early Signals of Efficacy?
3.11.3 MA09-hRPE: Phase 2 in Dry Age Related Macular Degeneration and Phase 1/2 for Myopic Macular Degeneration
3.11.4 Ocata Therapeutics Revenues, 2011-2013
3.11.5 Ocata Therapeutics: Outlook in Summary
3.12 From Procedures to Products: Cord Blood Stem Cell Approvals
3.12.1 Hemacord by New York Blood Center
3.12.2 HPC, Cord Blood by ClinImmune and University of Colorado Cord Blood Bank
3.12.3 Ducord by Duke University School of Medicine
3.12.4 Allocord by SSM Cardinal Glennon Children’s Medical Center
3.12.5 HPC, Cord Blood BLA 125432 by LifeSouth Community Blood Centers
4. Leading Asia-Pacific Stem Cell Technology Companies
4.1 South Korea: Moving Rapidly to Commercialisation for MSC Therapies – but is it Exercising Enough Caution?
4.2 India: An Emerging Stem Cell Industry
4.3 Japan: Has Been Less Active than other Asian Countries in hESC Research
4.4 China: Liberal Laws for Stem Cell Research
4.5 Mesoblast: Australian Company with Extensive Product Pipeline
4.5.1 Purchase of Prochymal from Osiris and Partnership with Lonza
4.5.2 Prochymal: World’s First Approved Stem Cell Drug Outside of South Korea – Currently has Limited Market Access
4.5.2.1 Prochymal: Culture Expanded and Able to Treat GvHD
4.5.2.2 Mesoblast also Evaluating Prochymal for Treatment of Crohn’s Disease
4.5.2.3 Prochyma: Revenue Forecast, 2015-2025
4.5.3 Mesoblast Evaluating MPCs for Treatment of Diabetes in Phase 2
4.5.4 Mesoblast Evaluating MPCs for Treatment of Rheumatoid Arthritis in Phase 2
4.5.5 CEP-41750 in Phase 3 for Congestive Heart Failure
4.5.6 Phase 2 Trial of MPCs in Acute Myocardial Infarction
4.5.7 Promising Preclinical Findings in Ischaemic Stroke
4.5.8 Phase 2 Trials of MPCs in Intervertebral Disc Repair and Spinal Fusion
4.5.9 Phase 3 Trial in Haematological Malignancies
4.5.10 Phase 2 in Wet AMD, Preclinical In Neurology
4.5.11 Mesoblast Revenues, 2012-2014
4.5.12 Mesoblast Outlook in Summary: Large and Diversified Development Pipeline
4.6 Reliance Life Sciences: Indian Company with Stem Cell Therapies Already on the Market
4.6.1 CardioRel – Already Available in the Indian Market
4.6.1.1 CardioRel: Revenue Forecast, 2015-2025
4.6.2 ReliNethra – The First Stem Cell Therapy in India
4.6.3 ReliNethra C and ReliCord
4.6.4 Reliance Life Sciences: Outlook in Summary – First out of the Gate in the Indian Market, but What about Global Reach?
4.7 Anterogen: South Korean Company with Products Already on the Market
4.7.1 Cupistem: World’s First Approved Stem Cell Product Derived from Adipose Tissue
4.7.2 Queencell: Stromal Vascular Fraction containing Autologous MSCs, and a Phase 1/2 Trial for Treatment of Tennis Elbow
4.7.3 Anterogen: Quick to Market, but How Much Remaining Potential?
4.8 Pharmicell
4.8.1 Hearticellgram-AMI, One of the First Approved Cardiovascular Stem Cell Treatments
4.8.1.1 Hearticellgram-AMI: Potential Difficulty Getting Approval in Markets outside South Korea?
4.8.1.2 Hearticellgram-AMI: Revenue Forecast, 2015-2025
4.8.2 Cerecellgram for Stroke in Phase 3 and Cerecellgram for Spinal Cord Injuries in Phase 2/3: Both Expected to Finish Early 2016
4.8.3 Immunocellgram for Cancers and Lungcellgram for Pulmonary Fibrosis: Both in Preclinical Stages
4.8.4 Cellgram for Erectile Dysfunction – Undergoing Phase 1, and a Treatment for Multiple System Atrophy, Completed Phase 1
4.8.5 Livercellgram for Hepatic Failure: Phase 2 Completed January 2015
4.8.6 Pharmicell Outlook in Summary: Quick to Market and Large Pipeline, but Needs to Make a Push to Expand out of South Korea
4.9 MEDIPOST
4.9.1 Cartistem: ‘World’s First Allogeneic Stem Cell Drug’
4.9.1.1 Cartistem: Revenue Forecast, 2015-2025
4.9.2 Neurostem: Undergoing Phase 1/2a Study
4.9.3 Pneumostem: Undergoing Phase 1 in Intraventricular Haemorrhage and Phase 2 in Bronchial Pulmonary Dysplasia
4.9.4 MEDIPOST Outlook in Summary: One Stem Cell Therapy Already on the Market and South Korea’s Largest Cord Blood Bank
4.10 Stempeutics
4.10.1 Stempeucel: Phase 2 Trials for CLI, Liver Cirrhosis and OA
4.10.2 Stempeucel for Various Other Indications
4.10.3 Alliance with Cipla
4.10.4 Stempeutics Outlook in Summary: Using Stempeucel to Treat a Range of Disorders
5. Leading European Stem Cell Technology Companies
5.1 Regulation in Europe
5.2 UK Leads in European Stem Cell R&D
5.3 TiGenix: Proprietary Technology Platform and Three Stem Cell Products in Development
5.3.1 ChondroCelect Already on the Market
5.3.2 eASC Technology Platform
5.3.3 Cx601: European Phase 3 Data Expected in July 2015
5.3.3.1 Cx601: TiGenix Partners with Lonza, and Will Have Another Phase 3 Trial in the US
5.3.4 Cx611: Phase 2 for Rheumatoid Arthritis, and Phase 1 for Severe Sepsis
5.3.5 Cx621 – Positive Results from Phase 1 Trial
5.3.6 TiGenix Outlook in Summary: Cx601 Reaching End of Development and Represents the Company’s Greatest Strength
5.4 Cardio3 BioSciences: Develops Regenerative Therapies for Cardiovascular Diseases
5.4.1 Cardio3’s Proprietary Cardiopoiesis Technology Platform – Can be Applied to Various Stem Cell Sources
5.4.2 C-Cure: Stem Cell Therapy for the Treatment of Heart Failure
5.4.2.1 Phase 3 Trial Begins Amid Controversy
5.4.3 Cardio3 Outlook in Summary: Targeting a Therapeutic Area with High Unmet Need
5.5 Apceth
5.5.1 Proprietary Technology Platform Delivers Therapeutic Genes Directly to the Target
5.5.2 Agenmestencel-T for the Treatment of GI-tract Adenocarcinoma
5.5.3 Alecmestencel-T for the Treatment of PAOD/CLI
5.5.4 Alecmestencel-L for the Treatment of GvHD
5.5.5 Apceth Outlook in Summary: A Variety of Industry Firsts and Positive Outlook, Although Pipeline is in Early Stages
5.6 ReNeuron: Targeting Areas of Unmet Medical Need
5.6.1 CTX Neural Cell Line: Provides Technical and Competitive Advantages
5.6.1.1 CTX for Stroke: Interim Results from P
ISCES Study Show Positive Results
5.6.1.2 CTX for Stroke: Currently Undergoing Phase 2 Study
5.6.1.3 CTX for Critical Limb Ischaemia: Undergoing Phase 1, will be Completed this Year
5.6.2 hRPCs for the Treatment of Retinitis Pigmentosa: In Late Preclinical Development, Will Begin Clinical Trials Soon
5.6.3 Exosome Technology Platform
5.6.4 Non-therapeutic Products: ReNcell VM and ReNcell CX, Licensed to Merck Millipore
5.6.5 Recent Developments in the Company
5.6.6 ReNeuron Revenue, 2011-2014
5.6.7 ReNeuron Outlook in Summary: Underlying Platform a Major Strength and Source of Competitive Advantage
6. Leading Israeli Stem Cell Technology Companies
6.1 Israel: A Strong Presence in Stem Cell Research
6.2 Gamida Cell
6.2.1 Novartis Buys 15% Equity, Likely to Acquire Fully in 2015, other Investors Include Elbit
6.2.2 NAM Technology Platform
6.2.3 Copper Chelator Based Technology
6.2.4 StemEx Shows Improved Survival at 100 Days, and Other Developments
6.2.5 NiCord – Aiming for a “Paradigm Shift” in Treatment Practice, Receives Orphan Drug Designation
6.2.6 Gamida Cell: Outlook in Summary
6.3 Cell Cure Neurosciences
6.3.1 Using Retinal Pigmented Epithelial Cells to Treat AMD, a Disease Affecting More Than 9 Million People in US
6.3.2 OpRegen and OpRegen Plus: Product Candidates for Dry AMD
6.3.3 Exclusive Licence Agreement with Teva for OpRegen and Possibly OpRegen Plus
6.3.4 Cell Cure Neurosciences: Outlook in Summary
6.4 Pluristem Therapeutics
6.4.1 PLX Cells: Secretes Therapeutic Proteins in Damaged Tissues
6.4.2 PLX-PAD for IC in Phase 2 and for CLI in Phase 1
6.4.3 PLX-PAD for Injured Gluteal Muscle in Phase 1/2 and for PAH in Phase 1
6.4.4 PLX-R18 for ARS, in Preclinical Development
6.4.5 Partnerships with United Therapeutics and CHA Bio & Disotech
6.4.6 Pluristem Therapeutics Revenue, 2012-2014
6.4.7 Pluristem Therapeutics Outlook in Summary: Proprietary Technology and PLX-PAD for Multiple Indications
7. Qualitative Analysis of the Stem Cell Technologies Market, 2015-2025
7.1 SWOT Analysis of the Stem Cell Technologies Market
7.2 Strengths
7.2.1 Recent Approvals of Stem Cell Therapies
7.2.2 Relaxation of Regulatory Barriers
7.2.3 Huge Number of Ongoing Clinical Trials – Should Lead to a Barrage of Approvals over the Coming Years
7.2.4 HSCT is Already an Established Procedure
7.3 Weaknesses
7.3.1 Phase 3 Trials Comprise Only a Small Fraction of Present Studies
7.3.2 Regulatory and Reimbursement Concerns
7.3.3 Uncertain Mechanism of Action in Some Stem Cell Therapies
7.4 Opportunities
7.4.1 Unmet Clinical Needs
7.4.2 Interactions with Related Technologies
7.4.3 Non-Therapeutic Uses: Cord Blood Banking and Cell-Based Assays
7.5 Threats
7.5.1 Financial Risks
7.5.2 Pipeline Failure
7.5.3 Long-term Safety Concerns
7.6 STEP Analysis of the Stem Cell Technologies Market
7.7 Social Factors
7.7.1 Increasing Burden of Disease
7.7.2 Biological Insurance through Stem Cell Banking
7.7.3 Stem Cell Tourism: Opportunities and Threats to the Market
7.8 Technological Factors
7.8.1 Increasing Research Output
7.8.2 IPSC Breakthroughs
7.8.3 Greater Understanding of Stem Cell Differentiation
7.8.4 Biomaterials, Bioprinting and Other Developments
7.8.5 CRISPRS: A Breakthrough in Genome Editing
7.9 Economic Factors
7.9.1 Grey Market for Stem Cell Therapies
7.9.2 Broad Changes in Healthcare Markets
7.9.3 New Business Models need to be Developed
7.10 Political Factors
7.10.1 Controversies and Ethical Objections over Embryonic Stem Cell Research
7.10.2 Strong Support from Some Governments
7.10.3 Pressure to Deregulate the Stem Cell Therapies Market
8. Research Interviews
8.1 Interview with Michael Hunt, Chief Financial Officer, ReNeuron
8.1.1 On the Current Status of ReNeuron’s Pipeline, and Thoughts on Expected Launch Dates and Revenues
8.1.2 ReNeuron’s Development in the Future, Its Biggest Strengths and Challenges and Thoughts on an Acquisition
8.1.3 On the Need for New Frameworks for Therapies and the Progress of the UK Government and Agencies in this Regard
8.1.4 On the Controversies Surrounding Stem Cells, the Global Stem Cell Industry, and Key Trends over the Next Ten Years
8.2 Interview with Steve Choi, Head of Investor Relations, MEDIPOST
8.2.1 On MEDIPOST’s Future and its Biggest Strengths, Opportunities and Challenges
8.2.2 On the Status and Development of its Products and Pipeline
8.2.3 On Competition and the South Korean Market in Relation to the World
8.3 Interview with Stefanos Theoharis, Chief Business Officer, Apceth
8.3.1 Apceth’s Current Aims, and its Development over the Next Ten Years
8.3.2 Apceth’s Greatest Strengths, Opportunities and Challenges
8.3.3 Current Status of the Pipeline, Competition, and Variations Among Markets Around the World
8.3.4 How the Stem Cell Industry Needs to Improve over the next Ten Years
8.4 Interview with Karine Kleinhaus, Divisional Vice President, North America, Pluristem
8.4.1 On Pluristem’s Development over the Next Ten Years
8.4.2 On Pluristem’s Greatest Strengths, Opportunities and Challenges
8.4.3 On the Status of Pluristem’s Pipeline and Results from Clinical Trials
8.4.4 On the Stem Cell Industry in the Next Ten Years
8.5 Interview with Yael Margolin, CEO, Gamida Cell
8.5.1 On the Market Potential of Stem Cell Therapy
8.5.2 On NiCord’s Therapeutic Potential and the Patients Being Targeted
8.5.3 On Immune Rejection, Advantages of Using Stem Cells and how NiCord Compares to Other Products in Clinical Development
8.5.4 Partnership with Teva, the Market Environment and Biggest Threats Facing the Industry
8.6 Interview with Robin Smith, Former CEO of NeoStem
8.6.1 On Whether Stem Cell Therapy can Revolutionise Medicine, as has been Suggested
8.6.2 Advantages of NeoStem’s VSEL Technology, and Target Indications for the Company’s Lead Product Candidate
8.6.3 NeoStem as part of Deloitte’s Technology Fast 500
8.6.4 The Issue of High Prices for Stem Cell Therapies and the Biggest Threats to the Stem Cell Market in the Next Decade
8.6.5 Diseases Generating the Most Interest for Stem Cell Treatment
9. Conclusions
9.1 The US Leads the Field for Stem Cell Research
9.2 Market Remains Under Capitalised, in Need of Financing
9.3 Industry has Many Barriers to Overcome
9.4 Competition Will Increase from 2015 to 2025
9.5 Concluding Remarks
【レポート販売概要】
■ タイトル：世界における主要な幹細胞技術企業分析2015-2025■ 英文：Pharma Leader Series: Top Stem Cell Technology Companies 2015-2025
■ 発行日：2015年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN5040804
■ 調査対象地域：グローバル
- エチレン・酢酸ビニル（EVA）の世界市場：VLEVA、LEVA、MEVA、HEVAThe global ethylene vinyl acetate (EVA) market size, in terms of value, is projected to reach USD 9.71 Billion by 2020, at a CAGR of 3.5% between 2015 and 2020. The high potential from the packaging and footwear & foam industry, increasing global demand for EVA in solar energy sector, and continuous expansion and merger & acquisition activities undertaken by different companies are the key factors …
- アトピー性皮膚炎：世界市場（医薬品市場予測及び分析～2022）PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2022 Summary Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit. _x000D_ By the mid-to-late term of GlobalDa …
- 世界のクラウドストレージ市場The growing online activities such as e-mail, enterprise resource planning, digital images, Salesforce automation, video surveillance and social networking data have led to an increase in unstructured data both large and small businesses. This explosion of big data has emerged as a challenge before business organization. Although organizations are increasing their IT budgets, however, in house man …
- 農業用フィルムの世界市場予測（～2022年）：ハウス用フィルム、サイレージフィルム、マルチフィルムThe global agricultural films market is estimated to be USD 7.92 Billion in 2017 and is projected to reach USD 10.57 Billion by 2022, at a CAGR of 5.9% from 2017 to 2022. Growing global population has led to an increased need for optimum agricultural productivity, which is consequently expected to boost the demand for agricultural films to increase yield and crop quality. In addition, increasing d …
- 生検用機器の世界市場2016-2020About Biopsy A biopsy is a medical procedure through which a part or full tissue is removed from an organ to examine the presence or extent of a disease. Biopsies are mostly performed in in the critical areas of the body such as the liver, lungs, prostate, and kidney using a wide range of devices. Technavio’s analysts forecast the global biopsy devices market to grow at a CAGR of: 6.41% during the …
- 大型屋外広告の世界市場2015-2019About spectacular advertising Spectacular outdoor advertising focuses on high traffic areas to stand out against all outdoor advertisements. It is a mass-market medium that is used to broadcast messages for branding and support campaigns. Outdoor advertising expenses are of two types, physical and digital. Physical outdoor media includes bulletin billboards while digital outdoor media includes med …
- JSC Gazprom Neft：石油・ガスバリューチェーン分析レポート2013JSC Gazprom Neft Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "JSC Gazprom Neft" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “JSC Gazprom Neft”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the com …
- 腰椎固定術の世界市場2016-2020About Spinal Fusion Spinal fusion surgery is performed in many forms, and all are designed to help limit the pain caused by joints through surgery depending on conditions such as degenerative disc disease (DDD), spondylosyndesis or spondylodesis, and other small problems caused in spine vertebrae. Spine surgery is mostly recommended by surgeons when they pinpoint the source of pain in the individu …
- 繊維セメントの世界市場予測（～2021）MarketsandMarkets projects that the market for fiber cement will grow from USD 13.75 Billion in 2016 to USD 17.38 Billion by 2021, at a CAGR of 4.80%. The market for fiber cement is growing due to growth in the construction industry and stringent regulations regarding the use of asbestos cement. Rising per capita income of the middle class has increased its purchasing power, which has resulted in …
- 慢性疲労症候群治療法の世界市場2019-2023Global Chronic Fatigue Syndrome Therapeutics Market: About this market Technavio’s chronic fatigue syndrome (CGS) therapeutics market analysis considers sales from pain relievers and NSAIDs, antidepressant and antipsychotic drugs, and antimicrobial and immunomodulatory drugs. Our analysis also considers the sales of chronic fatigue syndrome therapeutics in Asia, Europe, North America, and ROW. In …
- 2014年戦略提言：日本の診断市場This new report from Venture Planning Group provides an overview of the Japanese diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments: - Blood Banking - Cancer - Chemistry & …
- エネルギー貯蔵システム（ESS）用バッテリーの世界市場：リチウムイオンバッテリー、ナトリウムバッテリー、鉛バッテリーAbout battery energy storage Battery energy storage stores surplus electricity, which can be utilized during power shortages, blackouts, and peak demand. Surplus electricity generated is stored in batteries. This is supplied to customers when demand exceeds the amount generated. Various technologies such as Li-ion, lead-acid, sodium-sulphur, and other advanced battery technologies are available fo …
- ヒートポンプの世界市場2015-2019About Heat Pump A heat pump is an energy-efficient alternative for an air conditioner and furnace in places where the climatic conditions demand moderate heating and cooling needs. It consumes electric power and transfers heat from one space to another, depending on the climatic condition and its demand for either heating or cooling. Heat pump can be operated at a cost that is almost a quarter of …
- 高級マッサージチェアの世界市場2016-2020About Luxury Massage Chair Market Luxury massage chair market, one of the segments in the luxury furniture market, has been growing steadily over the years. It has high penetration in developed economies in North America and Europe. There has been increasing demand from countries such as China, Japan, South Korea, Singapore, and Australia due to its increased affordability. The majority of the wor …
- T細胞白血病(T-Cell Leukemia)：治療薬開発パイプライン動向（2015年上半期版）T-Cell Leukemia - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘T-Cell Leukemia - Pipeline Review, H1 2015’, provides an overview of the T-Cell Leukemia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of acti …
